Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
- 15 January 2017
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 23 (2), 370-378
- https://doi.org/10.1158/1078-0432.ccr-16-0150
Abstract
Purpose: To determine the expression level, associations, and biological role of PD-L1, IDO-1, and B7-H4 in non–small cell lung cancer (NSCLC). Experimental Design: Using multiplexed quantitative immunofluorescence (QIF), we measured the levels of PD-L1, IDO-1, B7-H4, and different tumor-infiltrating lymphoycte (TIL) subsets in 552 stages I–IV lung carcinomas from two independent populations. Associations between the marker levels, TILs, and major clinicopathologic variables were determined. Validation of findings was performed using mRNA expression data from The Cancer Genome Atlas (TCGA) and in vitro stimulation of lung adenocarcinoma A549 cells with IFNγ and IL10. Results: PD-L1 was detected in 16.9% and 21.8% of cases in each population. IDO-1 was expressed in 42.6% and 49.8%; and B7-H4 in 12.8% and 22.6% of cases, respectively. Elevated PD-L1 and IDO-1 were consistently associated with prominent B- and T-cell infiltrates, but B7-H4 was not. Coexpression of the three protein markers was infrequent, and comparable results were seen in the lung cancer TCGA dataset. Levels of PD-L1 and IDO-1 (but not B7-H4) were increased by IFNγ stimulation in A549 cells. Treatment with IL10 upregulated B7-H4 but did not affect PD-L1 and IDO-1 levels. Conclusions: PD-L1, IDO-1, and B7-H4 are differentially expressed in human lung carcinomas and show limited co-expression. While PD-L1 and IDO-1 are associated with increased TILs and IFNγ stimulation, B7-H4 is not. The preferential expression of discrete immune evasion pathways in lung cancer could participate in therapeutic resistance and support design of optimal clinical trials. Clin Cancer Res; 23(2); 370–8. ©2016 AACR.Other Versions
This publication has 33 references indexed in Scilit:
- Novel Recombinant Human B7-H4 Antibodies Overcome Tumoral Immune Escape to Potentiate T-Cell Antitumor ResponsesCancer Research, 2013
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortalScience Signaling, 2013
- Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human CancerClinical Cancer Research, 2013
- Indoleamine 2,3 dioxygenase and metabolic control of immune responsesTrends in Immunology, 2012
- IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis DevelopmentCancer Discovery, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- The Inhibitory Role of B7-H4 in Antitumor Immunity: Association with Cancer Progression and SurvivalClinical and Developmental Immunology, 2011
- Fine tuning the immune response through B7‐H3 and B7‐H4Immunological Reviews, 2009
- B7-H3 and B7-H4 expression in non-small-cell lung cancerLung Cancer, 2006
- B7x: A widely expressed B7 family member that inhibits T cell activationProceedings of the National Academy of Sciences of the United States of America, 2003